Overview

This trial is active, not recruiting.

Condition prostate cancer
Treatments docetaxel, goserelin acetate, leuprolide acetate, conventional surgery
Phase phase 3
Sponsor Cancer and Leukemia Group B
Collaborator National Cancer Institute (NCI)
Start date December 2006
End date June 2018
Trial size 750 participants
Trial identifier NCT00430183, CALGB-90203, CDR0000526353

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and leuprolide, may stop the adrenal glands from making androgens. Giving docetaxel and leuprolide or goserelin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether giving docetaxel and leuprolide or goserelin before surgery is more effective than surgery alone in treating patients with prostate cancer.

PURPOSE: This randomized phase III trial is studying docetaxel and leuprolide or goserelin to see how well they work when given before surgery compared with surgery alone in treating patients with high-risk localized prostate cancer.

United States California, Hawaii, Indiana, Louisiana, Michigan, Minnesota, Montana, New Jersey, New Mexico, New York, and 5 other states
Other Countries No locations recruiting

Study Design

Allocation randomized
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients receive goserelin subcutaneously or leuprolide acetate intramuscularly once every 4 or 12 weeks for 18-24 weeks (measured from the date of starting docetaxel). They also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 3 weeks for up to 6 courses. Within 60 days after completion of chemohormonal therapy, patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
docetaxel
Given IV over 1 hour
goserelin acetate
Given subcutaneously
leuprolide acetate
Given intramuscularly
conventional surgery
Patients undergo radical prostatectomy with staging pelvic lymphadenectomy
(Active Comparator)
Within 60 days after randomization, patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
conventional surgery
Patients undergo radical prostatectomy with staging pelvic lymphadenectomy

Primary Outcomes

Measure
3-year biochemical progression-free survival (bPFS) rate
time frame:

Secondary Outcomes

Measure
5-year bPFS rate and bPFS
time frame:
Time to clinical local recurrence
time frame:
Time to metastatic disease progression
time frame:
Unacceptable toxicity
time frame:
Prostate cancer-specific-free survival
time frame:
Disease progression
time frame:
Overall survival
time frame:
Death
time frame:

Eligibility Criteria

Male participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the prostate - No small cell, neuroendocrine, or transitional cell carcinoma - Clinically localized, stage T1-3a disease - No radiographic evidence of metastatic disease*, as demonstrated by all of the following: - No pelvic lymph nodes > 1.5 cm by CT scan or MRI of the abdomen and pelvis or endorectal MRI of the pelvis - A negative biopsy required for lymph node(s) that measure > 1.5 cm - If > 1 lymph node is > 1.5 cm, the largest or most accessible node is biopsied - Negative bone scan with plain films and/or MRI/CT scan confirmation, if necessary NOTE: *Positive positron emission tomography scan and Prostascint scans are not considered proof of metastatic disease - Serum prostate-specific antigen level ≤ 100 ng/mL within the past 6 weeks - Patients must have a known Gleason sum based on biopsy or TURP at study entry - High-risk disease, meeting 1 of the following criteria: - Probability of biochemical progression-free survival at 5 years after surgery < 60% by Kattan nomogram prediction - Biopsy Gleason score 8 to 10 - Deemed an appropriate candidate for radical prostatectomy PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - Life expectancy > 10 years - Absolute neutrophil count ≥ 1,500/mm^3 - Platelet count ≥ 150,000/mm^3 - Creatinine ≤ 2.0 mg/dL - Bilirubin normal (≤ 2.5 times upper limit of normal [ULN] for patients with Gilbert's disease) - AST and ALT ≤ 1.5 times ULN - Fertile patients must use effective contraception during and for ≥ 2 months after completion of study treatment - Not at high risk for cardiac complications - Prior deep venous thrombosis, pulmonary embolism, and/or cerebrovascular accident allowed PRIOR CONCURRENT THERAPY: - No prior treatment for prostate cancer, including surgery, pelvic lymph node dissection, radiotherapy, or chemotherapy - Prior transurethral resection of prostate allowed - Prior androgen-deprivation therapy (e.g., luteinizing hormone-releasing hormone agonists, antiandrogens, or both) lasting ≤ 4 months allowed - Concurrent systemic anticoagulation allowed - No other concurrent systemic therapy, including androgen-deprivation therapy for the treatment of the prostate cancer - No concurrent oral antiandrogens - No concurrent aprepitant - No other concurrent chemotherapeutic agents except for any of the following: - Steroids given for adrenal failure - Hormones administered for nondisease-related conditions (e.g., insulin for diabetes) - Intermittent use of dexamethasone as an antiemetic or as pretreatment for patients receiving docetaxel

Additional Information

Official title Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
Description OBJECTIVES: Primary - Compare the rate of 3-year biochemical progression-free survival (bPFS) in patients with high-risk, clinically localized prostate cancer treated with radical prostatectomy with vs without neoadjuvant chemohormonal therapy comprising docetaxel and androgen-deprivation therapy with leuprolide acetate or goserelin. Secondary - Compare the 5-year bPFS rate, bPFS, disease progression, disease-free survival, and overall survival of patients treated with these regimens. - Determine the safety and tolerability of neoadjuvant docetaxel and androgen-deprivation therapy in these patients. - Compare the time to clinically apparent local disease recurrence and metastatic disease in patients treated with these regimens. - Compare pathologic tumor stage, frequency of lymph node metastases, and positive margin rates in patients treated with these regimens. - Determine if changes in serum testosterone levels will predict bPFS in these patients. - Determine, prospectively, whether prostate-specific antigen doubling time is a surrogate endpoint for time to clinical metastases and overall survival in these patients. OUTLINE: This is a multicenter, randomized study. Patients are stratified according to nomogram-predicted biochemical progression-free survival at 5 years (0-20.9% vs 21-39.9% vs 40-59.9% vs ≥ 60%) and androgen-deprivation therapy in the past 3 months (no vs yes). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive goserelin subcutaneously or leuprolide acetate intramuscularly once every 4 or 12 weeks for 18-24 weeks (measured from the date of starting docetaxel). They also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 3 weeks for up to 6 courses. Within 60 days after completion of chemohormonal therapy, patients undergo radical prostatectomy with staging pelvic lymphadenectomy. - Arm II: Within 60 days after randomization, patients undergo radical prostatectomy with staging pelvic lymphadenectomy. After completion of study therapy, patients are followed at 1 and 3 months and then periodically for up to 15 years. PROJECTED ACCRUAL: A total of 750 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in February 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).
Location data was received from the National Cancer Institute and was last updated in August 2016.